Travere Therapeutics公司宣布，其创新药物Filspari®（Sparsentan）已获得美国食品药品监督管理局（FDA）的完全批准。这一里程碑式进展使该药物成为目前首个且唯一获批用于治疗局灶节段性肾小球硬化症（FSGS）的疗法。此次批准为患有这一罕见肾脏疾病的患者提供了新的治疗希望。
Travere Therapeutics公司宣布，其创新药物Filspari®（Sparsentan）已获得美国食品药品监督管理局（FDA）的完全批准。这一里程碑式进展使该药物成为目前首个且唯一获批用于治疗局灶节段性肾小球硬化症（FSGS）的疗法。此次批准为患有这一罕见肾脏疾病的患者提供了新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.